- iBio ( NYSE: IBIO ) on Tuesday announced an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease.
- The company said it recently completed its first manufacturing run of its proprietary nucleocapsid antigen under cGMP conditions using its FastPharming System.
- iBIO-202 uses a portion of the nucleocapsid "N" protein, which is more highly conserved. The N antigen is currently undergoing release testing and is intended for use in IBIO-202 clinical studies.
- ( IBIO ) has risen 1.7% .
For further details see:
iBio provides update on development of COVID-19 vaccine candidate